文献速递细菌感染、耐药与抗菌药物

MRSA血流感染早期换用达托霉素与继续万古霉素的疗效比较

Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究纳入2007-2014年124家退伍军人医院收治的7411例MRSA血流感染患者,比较换用达托霉素与继续万古霉素对30天死亡率的影响。多因素分析显示,在开始万古霉素3天内换用达托霉素与较低的30天死亡率显著相关(HR=0.48;

要点

  • MRSA血流感染患者早期(3天内)换用达托霉素与30天死亡率降低显著相关。
  • 首次住院期间任何时间换用达托霉素与30天死亡率无显著关联。
  • 研究提示早期换药可能获益,但需前瞻性研究验证。

核心结论

  • 在开始万古霉素3天内换用达托霉素与MRSA血流感染患者较低的30天死亡率显著相关,而较晚换药未见此获益。

研究设计与样本

  • 回顾性队列研究,纳入2007-2014年124家退伍军人医院收治的7411例接受万古霉素治疗的MRSA血流感染患者。

主要发现

  • 606例(8.2%)在首次住院期间换用达托霉素,108例(1.5%)在开始万古霉素3天内换用。

临床怎么用

  • 对于MRSA血流感染患者,若考虑换用达托霉素,早期(开始万古霉素3天内)换药可能与较低30天死亡率相关。

局限性

  • 研究为回顾性设计,可能存在残余混杂,且结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA BSI) usually receive initial treatment with vancomycin but may be switched to daptomycin for definitive therapy, especially if treatment failure is suspected. Our objective was to evaluate the effectiveness of switching from vancomycin to daptomycin compared with remaining on vancomycin among patients with MRSA BSI. METHODS: Patients admitted to 124 Veterans Affairs Hospitals who experienced MRSA BSI and were treated with vancomycin during 2007-2014 were included. The association between switching to daptomycin and 30-day mortality was assessed using Cox regression models. Separate models were created for switching to daptomycin any time during the first hospitalization and for switching within 3 days of receiving vancomycin. RESULTS: In total, 7411 patients received vancomycin for MRSA BSI. Also, 606 (8.2%) patients switched from vancomycin to daptomycin during the first hospitalization, and 108 (1.5%) switched from vancomycin to daptomycin within 3 days of starting vancomycin. In the multivariable analysis, switching to daptomycin within 3 days was significantly associated with lower 30-day mortality (hazards ratio [HR] = 0.48; 95% confidence interval [CI]: .25, .92). However, switching to daptomycin at any time during the first hospitalization was not significantly associated with 30-day mortality (HR: 0.87; 95% CI: .69, 1.09). CONCLUSIONS: Switching to daptomycin within 3 days of initial receipt of vancomycin is associated with lower 30-day mortality among patients with MRSA BSI. This benefit was not seen when the switch occurred later. Future studies should prospectively assess the benefit of early switching from vancomycin to other anti-MRSA antibiotics.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schweizer ML, Richardson K, Vaughan Sarrazin MS, et al. Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections. Clin Infect Dis. 2021. PMID: 33512521. doi:10.1093/cid/ciaa1572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。